- Home
- ALXO vs ASRT Comparison
ALXO vs ASRT Comparison
Compare ALXO & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ASRT
- Stock Information
- Founded
- ALXO 2015
- ASRT 1995
- Country
- ALXO United States
- ASRT United States
- Employees
- ALXO N/A
- ASRT N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ALXO Health Care
- ASRT Health Care
- Exchange
- ALXO Nasdaq
- ASRT Nasdaq
- Market Cap
- ALXO 79.7M
- ASRT 69.2M
- IPO Year
- ALXO 2020
- ASRT 1997
- Fundamental
- Price
- ALXO $1.47
- ASRT $0.71
- Analyst Decision
- ALXO Strong Buy
- ASRT Strong Buy
- Analyst Count
- ALXO 6
- ASRT 1
- Target Price
- ALXO $3.30
- ASRT $3.00
- AVG Volume (30 Days)
- ALXO 356.5K
- ASRT 734.7K
- Earning Date
- ALXO 11-07-2025
- ASRT 11-10-2025
- Dividend Yield
- ALXO N/A
- ASRT N/A
- EPS Growth
- ALXO N/A
- ASRT N/A
- EPS
- ALXO N/A
- ASRT N/A
- Revenue
- ALXO N/A
- ASRT $137,354,000.00
- Revenue This Year
- ALXO N/A
- ASRT N/A
- Revenue Next Year
- ALXO N/A
- ASRT $4.10
- P/E Ratio
- ALXO N/A
- ASRT N/A
- Revenue Growth
- ALXO N/A
- ASRT 9.22
- 52 Week Low
- ALXO $0.40
- ASRT $0.51
- 52 Week High
- ALXO $2.27
- ASRT $1.08
- Technical
- Relative Strength Index (RSI)
- ALXO 49.39
- ASRT 36.93
- Support Level
- ALXO $1.29
- ASRT $0.73
- Resistance Level
- ALXO $1.56
- ASRT $0.79
- Average True Range (ATR)
- ALXO 0.18
- ASRT 0.06
- MACD
- ALXO 0.01
- ASRT -0.01
- Stochastic Oscillator
- ALXO 65.90
- ASRT 18.51
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.